These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 20448071

  • 41. The new FDA labeling for ESA--implications for patients and providers.
    Manns BJ, Tonelli M.
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):348-53. PubMed ID: 22266575
    [Abstract] [Full Text] [Related]

  • 42. Health-related quality of life and hemoglobin levels in chronic kidney disease patients.
    Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, Soroka S, Mujais S.
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):33-8. PubMed ID: 18987300
    [Abstract] [Full Text] [Related]

  • 43. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
    Bohlius J, Tonia T, Schwarzer G.
    Acta Haematol; 2011 Jan; 125(1-2):55-67. PubMed ID: 21150188
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M, Mueller BA, Segal JH.
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [Abstract] [Full Text] [Related]

  • 49. Hemoglobin variability in anemia of chronic kidney disease.
    Kalantar-Zadeh K, Aronoff GR.
    J Am Soc Nephrol; 2009 Mar; 20(3):479-87. PubMed ID: 19211716
    [Abstract] [Full Text] [Related]

  • 50. [Anemia: guidelines comparison].
    Del Vecchio L.
    G Ital Nefrol; 2009 Mar; 26(6):686-94. PubMed ID: 19918751
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Drug Saf; 2012 Nov; 11(6):923-31. PubMed ID: 22916722
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care.
    Schiller B, Besarab A.
    Curr Med Res Opin; 2011 Aug; 27(8):1539-50. PubMed ID: 21682552
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR, Dunst J, Vaupel P.
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.